Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianming Xu(Chinese PLA General Hospital), Yun Chen(Fudan University Shanghai Cancer Center), Wu Zhuang(Fujian Provincial Cancer Hospital), Yiping Zhang(Zhejiang Cancer Hospital), Zhendong Chen(Anhui Medical University), Jia Chen(Jiangsu Cancer Hospital), Helong Zhang(Air Force Medical University), Zuoxing Niu(Shandong First Medical University), Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Lizhu Lin(First Affiliated Hospital of Guangzhou Medical University), Kangsheng Gu(Anhui Medical University), Ying Liu(Zhengzhou University), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Zhanhui Miao(First Affiliated Hospital of Xinxiang Medical University), Xiaodong Jiang(The First People’s Hospital of Lianyungang), Ming Zeng(Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital), Jianhua Chen(Central South University), Zhichao Fu, Lu Gan(First Affiliated Hospital of Chongqing Medical University), Jun Wang(Hebei Medical University), Xianbao Zhan(Second Military Medical University), Tianshu Liu(The First Affiliated Hospital, Sun Yat-sen University), Zhiping Li(Jiangxi Provincial Cancer Hospital), Lin Shen(Peking University), Yongqian Shu(Jiangsu Province Hospital), Tao Zhang(Jiangsu Hengrui Medicine (China)), Qing Yang(Jiangsu Hengrui Medicine (China)), Jianjun Zou(Jiangsu Hengrui Medicine (China)), Suxia Luo, Feng Peng, Gang Wu(Fujian Provincial Cancer Hospital), Nong Xu(Chinese PLA General Hospital), Lin Zhao(Peking University Cancer Hospital), Dong Ma(The First People’s Hospital of Lianyungang), Shukui Qin(Jiangsu Hengrui Medicine (China)), Wei Ren, Enxiao Li(Peking University), Hongda Lu(First Affiliated Hospital of Chongqing Medical University), Yueyin Pan, Jianping Xiong, Ying Yuan(Henan Cancer Hospital), Yuxian Bai, Lei Chen(Central South University), Yi Hu(Jiangsu Province Hospital), Li Zhang(Jiangsu Hengrui Medicine (China)), Yong Gao(Jiangsu Province Hospital)
Cited by 582
Abstract
Related Papers
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al.|CA A Cancer Journal for Clinicians|2018|87.6k
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara, Nancy R. Zhang, Ellie Corigliano et al.|Archives of Pathology & Laboratory Medicine|2018|534